Evidence of Artemisinin-Resistant Malaria in Africa
- PMID: 34551228
- DOI: 10.1056/NEJMoa2101746
Evidence of Artemisinin-Resistant Malaria in Africa
Abstract
Background: In the six Southeast Asian countries that make up the Greater Mekong Subregion, Plasmodium falciparum has developed resistance to derivatives of artemisinin, the main component of first-line treatments for malaria. Clinical resistance to artemisinin monotherapy in other global regions, including Africa, would be problematic.
Methods: In this longitudinal study conducted in Northern Uganda, we treated patients who had P. falciparum infection with intravenous artesunate (a water-soluble artemisinin derivative) and estimated the parasite clearance half-life. We evaluated ex vivo susceptibility of the parasite using a ring-stage survival assay and genotyped resistance-related genes.
Results: From 2017 through 2019, a total of 14 of 240 patients who received intravenous artesunate had evidence of in vivo artemisinin resistance (parasite clearance half-life, >5 hours). Of these 14 patients, 13 were infected with P. falciparum parasites with mutations in the A675V or C469Y allele in the kelch13 gene. Such mutations were associated with prolonged parasite clearance half-lives (geometric mean, 3.95 hours for A675V and 3.30 hours for C469Y, vs. 1.78 hours for wild-type allele; P<0.001 and P = 0.05, respectively). The ring-stage survival assay showed a higher frequency of parasite survival among organisms with the A675V allele than among those with the wild-type allele. The prevalence of parasites with kelch13 mutations increased significantly, from 3.9% in 2015 to 19.8% in 2019, due primarily to the increased frequency of the A675V and C469Y alleles (P<0.001 and P = 0.004, respectively). Single-nucleotide polymorphisms flanking the A675V mutation in Uganda were substantially different from those in Southeast Asia.
Conclusions: The independent emergence and local spread of clinically artemisinin-resistant P. falciparum has been identified in Africa. The two kelch13 mutations may be markers for detection of these resistant parasites. (Funded by the Japan Society for the Promotion of Science and others.).
Copyright © 2021 Massachusetts Medical Society.
Comment in
-
Emergence of Artemisinin-Resistant Plasmodium falciparum in East Africa.N Engl J Med. 2021 Sep 23;385(13):1231-1232. doi: 10.1056/NEJMe2110659. N Engl J Med. 2021. PMID: 34551233 No abstract available.
-
Evidence of Artemisinin-Resistant Malaria in Africa.N Engl J Med. 2022 Apr 7;386(14):1385-1386. doi: 10.1056/NEJMc2117480. N Engl J Med. 2022. PMID: 35388682 Free PMC article. No abstract available.
-
Evidence of Artemisinin-Resistant Malaria in Africa. Reply.N Engl J Med. 2022 Apr 7;386(14):1386. doi: 10.1056/NEJMc2117480. N Engl J Med. 2022. PMID: 35388683 No abstract available.
Similar articles
-
Indigenous emergence and spread of kelch13 C469Y artemisinin-resistant Plasmodium falciparum in Uganda.Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0165923. doi: 10.1128/aac.01659-23. Epub 2024 Jul 19. Antimicrob Agents Chemother. 2024. PMID: 39028193
-
Emerging threat of artemisinin partial resistance markers (pfk13 mutations) in Plasmodium falciparum parasite populations in multiple geographical locations in high transmission regions of Uganda.Malar J. 2024 Nov 5;23(1):330. doi: 10.1186/s12936-024-05158-9. Malar J. 2024. PMID: 39501325 Free PMC article.
-
The Impact of Sequestration on Artemisinin-Induced Parasite Clearance in Plasmodium falciparum Malaria in Africa.Clin Infect Dis. 2023 May 3;76(9):1585-1593. doi: 10.1093/cid/ciac944. Clin Infect Dis. 2023. PMID: 36519341
-
Artemisinin Action and Resistance in Plasmodium falciparum.Trends Parasitol. 2016 Sep;32(9):682-696. doi: 10.1016/j.pt.2016.05.010. Epub 2016 Jun 9. Trends Parasitol. 2016. PMID: 27289273 Free PMC article. Review.
-
A review of the frequencies of Plasmodium falciparum Kelch 13 artemisinin resistance mutations in Africa.Int J Parasitol Drugs Drug Resist. 2021 Aug;16:155-161. doi: 10.1016/j.ijpddr.2021.06.001. Epub 2021 Jun 10. Int J Parasitol Drugs Drug Resist. 2021. PMID: 34146993 Free PMC article. Review.
Cited by
-
Polymorphisms in the Pfcrt, Pfmdr1, and Pfk13 genes of Plasmodium falciparum isolates from southern Brazzaville, Republic of Congo.Sci Rep. 2024 Nov 14;14(1):27988. doi: 10.1038/s41598-024-78670-2. Sci Rep. 2024. PMID: 39543235 Free PMC article.
-
Optimization of in vivo antimalarial efficacy of combinations of aqueous leaf extracts of Artemisia annua L., Vernonia amygdalina Del, and Microglossa pyrifolia (Lam.) Kuntze using factorial design.BMC Complement Med Ther. 2024 Nov 13;24(1):393. doi: 10.1186/s12906-024-04691-z. BMC Complement Med Ther. 2024. PMID: 39538287 Free PMC article.
-
Artemisinin-resistant Plasmodium falciparum Kelch13 mutant proteins display reduced heme-binding affinity and decreased artemisinin activation.Commun Biol. 2024 Nov 13;7(1):1499. doi: 10.1038/s42003-024-07178-2. Commun Biol. 2024. PMID: 39538019 Free PMC article.
-
Plasmodium vivax antigen candidate prediction improves with the addition of Plasmodium falciparum data.NPJ Syst Biol Appl. 2024 Nov 13;10(1):133. doi: 10.1038/s41540-024-00465-y. NPJ Syst Biol Appl. 2024. PMID: 39537634 Free PMC article.
-
Subclinical malaria among pregnant women living in refugee settlements in Northern Uganda.Ther Adv Infect Dis. 2024 Nov 6;11:20499361241296002. doi: 10.1177/20499361241296002. eCollection 2024 Jan-Dec. Ther Adv Infect Dis. 2024. PMID: 39513092 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- Health and Labour Sciences Research Grants/H26-Iry/Ministry of Health, Labour and Welfare
- G2013-105/Global Health Innovative Technology Fund
- G2015-210/Global Health Innovative Technology Fund
- JP15km0908001/Japan Agency for Medical Research and Development
- Grants-in-aid for scientific research/17H04074/Japan Society for the Promotion of Science
LinkOut - more resources
Full Text Sources